Build a diversified product matrix centered on T cells
GRIT Bio focuses on the R&D and commercialization of next-generation T cell therapies. We have built a comprehensive T cell product portfolio covering multiple technology platforms and treatment scenarios, centered on personalized T cell therapies, functional enhancement of cell therapies, off-the-shelf solutions, and in vivo programming. Guided by critical clinical needs in oncology and autoimmune diseases, we are advancing innovative technologies including tumor-infiltrating lymphocyte (TIL) therapy, allogeneic universal cell therapy, in vivo CAR-T, and tumor neoantigen vaccines. Leveraging our proprietary cell screening, gene editing, in vivo delivery, and manufacturing platforms, we are driving the evolution of T cell therapies toward more efficient, accessible, and precise treatment models.
Explore our core productsTechnical Platform
Deepening expertise in cell therapy by building a comprehensive technical system from R&D to clinical application
StemTexp®Dry TIL Expansion Technology Platform
- ●Proprietary platform for global intellectual property protection
- ●Completed 400+ batches of TIL development and production
- ●Preparation success rate ≥ 90%
- ●Enriched with memory T cells
StaViral®Stable Cell Line Production Platform
- ●High-quality, cost-effective GMP retroviral vector production
ImmuT Finder®Immunomodulatory Target Discovery Platform
- ●High-Throughput Screening of Novel Immune Targets
- ●Identify key immune regulatory targets to overcome challenges posed by cold tumor TMEs.
- ●Develop first-in-class products with strong safety and efficacy profiles.
KOReTIL®Efficient TIL Gene Knockout System
- ●TIL DP knockout rate ≥ 90%
- ●Parallelly validate the functions of multiple targets
NEOVigator®Neoantigen Discovery Platform
- ●Multi-dimensional High-Throughput Screening
- ●Functional validation using autologous TILs and PBMCs
- ●Proprietary AI algorithms optimize immunogenicity prediction
- ●Neoantigen prediction accuracy is 10 times higher than traditional methods.
LNP delivery technology targeting APC
- ●Targeted delivery to multiple organs via APCs with minimized off-target accumulation in the liver
- ●Achieve potent antigen-specific T cell responses at doses 10 times lower than LPX
- ●Highly efficient, safe proprietary ionizable lipids for repeated immunization
OptiDiff®General Cell Expansion Platform
- ●Universal CAR-iNKT Cell Differentiation and Expansion Platform
- ●5 Week 10^7X Amplification Process
- ●Ultra-high purity ≥ 95%
- ●Cost-effective mass production
LNP delivery technology targeting T cells
- ●Fully customizable platform based on proprietary ionizable lipids and conjugation technology
- ●Achieve 10-60x dose reduction through ultra-efficient T cell targeting
- ●Superior safety with minimized myeloid and liver expression
- ●Significant manufacturing and cost advantages
TgVec®Viral Vector Delivery Platform
- ●High Affinity
- ●low immunogenicity
- ●Unlock scalable production potential
News Center
Get the latest updates on GRIT Bio
